Krystal Biotech, Inc. Common Stock (KRYS) — Analysis Summary
Krystal Biotech, Inc. Common Stock (KRYS) has a market cap of $9.11B with year-over-year revenue growth of +33.9%. Net margin stands at 52.6%. The stock trades at a P/E ratio of 40.5.
Key Takeaways
- Revenue changed +33.9% year-over-year
- Net margin of 52.6%
- P/E ratio of 40.5
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, KRYS posted revenue growth of +33.9% and trades at a P/E of 40.5.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.